TrialJournal of healthcare engineering2021

Safety of Anlotinib Capsules Combined with PD-1 Inhibitor Camrelizumab in the Third-Line Treatment of Advanced Non-Small-Cell Lung Cancer and Their Effect on Serum Tumor Markers.

Yinhua Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.